Omeros Corporation (NASDAQ:OMER) shares saw unusually-strong trading volume on Tuesday . Approximately 320,544 shares were traded during mid-day trading, a decline of 20% from the previous session’s volume of 402,541 shares.The stock last traded at $11.56 and had previously closed at $11.23.

Several analysts have recently commented on OMER shares. Maxim Group restated a “buy” rating and issued a $30.00 target price on shares of Omeros Corporation in a research note on Wednesday, March 9th. WBB Securities reaffirmed a “buy” rating and issued a $75.00 price target on shares of Omeros Corporation in a research report on Tuesday, June 14th. Cantor Fitzgerald started coverage on shares of Omeros Corporation in a research report on Thursday, June 2nd. They issued a “buy” rating and a $21.00 price target on the stock. FBR & Co reaffirmed an “outperform” rating and issued a $38.00 price target on shares of Omeros Corporation in a research report on Wednesday, June 29th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $62.00 price target on shares of Omeros Corporation in a research report on Tuesday, May 10th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $38.22.

The stock’s market cap is $443.79 million. The company has a 50-day moving average of $11.05 and a 200-day moving average of $12.38.

Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.11. The firm had revenue of $7.40 million for the quarter, compared to analysts’ expectations of $8.79 million. The company’s revenue was up 1797.4% on a year-over-year basis. During the same period last year, the business posted ($0.51) earnings per share. Equities analysts forecast that Omeros Corporation will post ($1.76) earnings per share for the current year.

In other news, VP Marcia S. Kelbon sold 15,900 shares of the company’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $9.94, for a total transaction of $158,046.00. Following the completion of the transaction, the vice president now directly owns 179,497 shares of the company’s stock, valued at $1,784,200.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

A number of institutional investors recently added to or reduced their stakes in the company. Mutual of America Capital Management LLC increased its position in Omeros Corporation by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 116,171 shares of the biopharmaceutical company’s stock worth $1,827,000 after buying an additional 694 shares during the last quarter. California State Teachers Retirement System increased its position in Omeros Corporation by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 70,144 shares of the biopharmaceutical company’s stock worth $1,103,000 after buying an additional 1,249 shares during the last quarter. Nationwide Fund Advisors increased its position in Omeros Corporation by 183.9% in the fourth quarter. Nationwide Fund Advisors now owns 69,700 shares of the biopharmaceutical company’s stock worth $1,096,000 after buying an additional 45,145 shares during the last quarter. Brown Advisory Inc. increased its position in Omeros Corporation by 44.6% in the fourth quarter. Brown Advisory Inc. now owns 529,699 shares of the biopharmaceutical company’s stock worth $8,332,000 after buying an additional 163,306 shares during the last quarter. Finally, Bank of Montreal Can increased its position in Omeros Corporation by 52.0% in the fourth quarter. Bank of Montreal Can now owns 1,327,706 shares of the biopharmaceutical company’s stock worth $20,885,000 after buying an additional 454,055 shares during the last quarter.

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product Omidria is approved in the United States for use during cataract surgery or intraocular lens (IOL), which is replacement surgery, to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.